A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Clinical trial NCT06609226 · RECRUITING

Trial details

NCT number: NCT06609226
Sponsor: Novo Nordisk A/S
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Sickle Cell Disease Thalassemia

Start date: 2025-01-10
Primary completion: 2030-12-30
Enrollment: 480

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.